Analyst Group has commented on Chordate Medical’s 2022 Q4 report. The analyst responsible confirms Anders Weilandt CEO Anders Weilandt’s view that the implementation and outcome of the migraine study is the single most important milestone in Chordate’s history. Now the company can fully focus on the final part of building the company; demonstrating Proof of Concept, i.e. measurable market share, that can lead to an exit.
Analyst Group highlights a transaction in which Pfizer is buying Biohaven Pharmaceutical:
“On May 10, 2022, Pfizer announced that it has entered into a definitive agreement to acquire Biohaven Pharmaceutical, which has developed the Nurtec ODT drug product, which is used for both acute migraine as well as prevention, where Pfizer itself expects to grow sales of Biohaven’s products to a peak sales level of $6 billion. We see this as clear evidence of the strategy of many large medtech and pharma players, i.e. that these players benefit more from acquiring smaller companies that have demonstrated proof of concept and have significant market potential, rather than developing innovative treatments themselves, in-house.”
